Stockwinners Market Radar for December 05, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:39 EST Coupang director sells $7.47M in common stock - In a regulatory filing, Coupang disclosed that its director Benjamin Sun sold 373K shares of common stock on December 1st in a total transaction size of $7.47M.

19:13 EST News Corp. special committee to explore combination with Fox Corp. - )News Corp (NWS) Special Committee composed solely of independent and disinterested members of the News Corp Board of Directors "formed to explore a potential combination with Fox Corp (FOXA) following receipt of letters from K. Rupert Murdoch and the Murdoch Family Trust, provided an update on the process in response to recent investor inquiries. The Special Committee is made up of all the independent directors not affiliated with the Murdoch family--Kelly Ayotte, Jose Maria Aznar, Natalie Bancroft, Ana Paula Pessoa, Masroor Siddiqui-and is chaired by Mr. Siddiqui, News Corp's Lead Independent Director. The Special Committee has been delegated full authority to evaluate the Proposed Transaction. The letters indicated that Mr. Murdoch and the Murdoch Family Trust will not vote in favor of a transaction unless it is both recommended by the Special Committee and approved by a majority vote of the shares held by non-affiliated stockholders entitled to vote."

18:42 EST Owens Corning completes sale of Russian operations, affirms Q4 guidance - Following its decision earlier this year to exit the Russian market, Owens Corning announced that it has completed the sale of its operations in the country to Umatex, a Russia-based producer of carbon fiber and fiber-based items. Financial terms of the sale were not disclosed. In conjunction with the announcement, the company reaffirmed its guidance of modest growth in net sales and earnings for the enterprise in the fourth quarter compared with the same period in 2021.

18:32 EST Wingstop CEO: Our business is experiencing meaningful deflation - In an interview on CNBC's Mad money, Michael Skipworth said, "We've got plenty of inventory." He expects a favorable commodity backdrop for 2023 with strong comp growth. "We're set up for a 19th quarter of consecutive growth," he added.

18:25 EST Ulta Beauty CEO: Consumer is loving what we are offering - In an interview on CNBC's Mad Money, Dave Kimbell said Ulta saw broad based strength across the business in Q3. The company's positive culture is holding it together and attracting new talent, Kimball said. "We are staffed and ready to go for the holiday season." Ulta continues to bring in new customers and reactivate old ones, with Gen Z representing a strong growth opportunity, Kimbell noted.

18:15 EST Palo Alto Networks director sells $6.4M in common stock - In a regulatory filing, Palo Alto Networks disclosed that its CTO Nir Zuk sold 36K share of common stock on December 1st in a total transaction size of $6.4M.

18:08 EST Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials - Mirati Therapeutics announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the tolerability and feasibility of a concurrent combination regimen of a KRASG12C inhibitor and a PD-1/L1 checkpoint inhibitor. The KRYSTAL-7 and KRYSTAL-1 trials represent the largest dataset evaluating a KRASG12C inhibitor in combination with a PD-1/L1 checkpoint inhibitor as a first-line treatment for patients with NSCLC harboring a KRASG12C mutation. 75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months. Treatment-related adverse events were Grade 1-2 (39%), Grade 3 (40%) and Grade 4 (4%); there were no Grade 5 TRAEs observed. TRAEs led to discontinuation of both adagrasib and pembrolizumab in 2 patients and only pembrolizumab in 2 patients; there were no patients who discontinued only adagrasib due to a TRAE. Increases in alanine transaminase/ aspartate transaminase were consistent with either agent as a monotherapy with Grade 3 TRAEs being highest grade and total incidence of Grade 3 liver function test increases of 9%. Median time from onset to an increase in ALT and AST was 26 and 37 days, respectively and only 1 patient experienced new onset treatment-related ALT/AST increase after 3 months. Of patients who were clinically evaluable and received at least one on-study scan, adagrasib and pembrolizumab demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate of 49%. In a subset of response-evaluable patients enrolled at least 6 months prior to the data cutoff date, 6 of 26 clinical responses occurred at second on-study scan or later, and the ORR was 56%. 7 evaluable patients enrolled in the KRYSTAL-1 Phase 1b cohort reported an ORR of 57% and a disease control rate of 100%. The four patients who responded maintained response for over nine months while two continued to receive treatment and remain in response beyond 18 months. Safety in the KRYSTAL-1 Phase 1b cohort was consistent with what has been observed in KRSTYAL-7 and demonstrated a manageable safety profile with no Grade 4-5 TRAEs. "Initial results across all cohorts suggest the concurrent combination of adagrasib and pembrolizumab may provide a chemotherapy-free option for treatment-naive NSCLC with a manageable safety profile and encouraging clinical activity," said Pasi A. Janne, MD, PhD, Dana Farber Cancer Institute. "Across all evaluated cohorts, liver-related TRAEs were predominantly low grade and occurred early in treatment, with limited new onset after 3 months."

18:01 EST Gol Linhas announces preliminary November traffic figures - Highlights: GOL's total supply increased 29.7%. Total seats increased 29.2% and the number of departures increased by 26.5%. GOL's total demand increased by 28.5% and the load factor was 81.3%. GOL's domestic supply increased 19.6% and demand increased by 18.7%. GOL's domestic load factor was 81.8%. The volume of departures increased by 22.1% and seats increased by 24.8%. GOL's international supply was 350M, the demand was 269M and international load factor was 76.9%.

17:48 EST Topgolf Callaway CEO buys $216K in common stock - In a regulatory filing, Topgolf Callaway disclosed that its CEO Oliver Brewer bought 10K shares of common stock on December 2 in a total transaction size of $216K.

17:41 EST Sumo Logic jumps 10% to $7.95 after Q3 earnings beat

17:25 EST Silvergate Capital says all customers still have access to deposits - In a regulatory 8-K filing, Silvergate Capital CEO Alan Lane writes: "It has been a very difficult few weeks for the digital asset industry, as we have all come to terms with the apparent misuse of customer assets and other lapses of judgment by FTX and Alameda Research. There has also been plenty of speculation - and misinformation - being spread by short sellers and other opportunists trying to capitalize on market uncertainty. As always, over the past few weeks Silvergate's first priority has been serving our customers as they navigate this incredibly volatile environment. I'm proud that all of our customers continue to have access to their U.S. dollar deposits when they need them and that the Silvergate Exchange Network ("SEN") has continued to operate uninterrupted throughout this period. I wanted to take this opportunity to set the record straight about Silvergate's role in the digital asset ecosystem and what we have always done, and continue to do, to ensure our customers act in accordance with our robust risk management controls. We take risk management and compliance extremely seriously. Silvergate operates in accordance with the Bank Secrecy Act and the USA PATRIOT Act. For each and every account, these laws require us to determine the beneficial owner, the source of funds, and the purpose and expected use of funds. Silvergate also monitors transaction activity for every account and identifies activity outside of the expected usage. When we identify certain kinds of activity, we are required to file suspicious activity reports, and we do so routinely. We have a track record of closing accounts that are used for purposes outside of the expected use. This is no small undertaking. We have invested, and will continue to invest, in systems and procedures to help ensure we are conducting effective customer due diligence and monitoring. We have dedicated a substantial number of Silvergate employees to this effort. And, as our customers can attest, the onboarding process can take weeks as a result of the time we spend gathering and reviewing information and documentation from prospective customers. After accounts are open, we continue to monitor account activity as part of our enhanced due diligence process on each of these accounts and to take action when there are red flags. By performing our risk management procedures and fulfilling our regulatory obligations, Silvergate plays a key role in helping law enforcement identify bad actors. We take this responsibility seriously. We conducted extensive due diligence on FTX and Alameda Research. Silvergate conducted significant due diligence on FTX and its related entities including Alameda Research, both during the onboarding process and through ongoing monitoring, in accordance with our risk management policies and procedures and the requirements outlined above. Alameda Research operated an over-the-counter (OTC) trading firm and individuals or entities engaging in OTC trades with Alameda would have been instructed by Alameda to send funds to Alameda's account whether at Silvergate or any of their other banking partners. Further, when a wire is originated, the individual or entity sending the funds instructs every detail to their bank, including to whom they want the funds sent. A receiving bank validates that the name of the beneficiary matches the name on the account and credits it accordingly. When Silvergate received payments directed to Alameda Research and credited it to the account of the same name, this was consistent with the instructions from the sender of the wire and industry practice. And, as I've noted previously, if we detect activity that is unexpected or potentially concerning in any account, we conduct an investigation and, when required, confidentially file a suspicious activity report in accordance with federal regulation. We have a resilient balance sheet and ample liquidity. While this has been a turbulent time in the digital asset industry, our customers' deposits are, and have always been, safely held. In addition to the cash we carry on our balance sheet, our entire investment securities portfolio can be pledged for borrowings at the Federal Home Loan Bank, other financial institutions, and the Federal Reserve Discount Window - and can ultimately be sold should we need to generate liquidity to satisfy customer withdrawal request. We intentionally carry cash and securities in excess of our digital asset related deposit liabilities. We purpose-built this business to support our customers not only during periods of growth but also in periods of volatility - that is, our business is designed to accommodate deposit inflows and outflows under a range of market conditions. I am eternally grateful to our employees for continuing to work hard in the face of so much uncertainty, and to our customers for their continued support. We look forward to continuing to provide a safe and reliable banking solution for the digital asset industry."

17:13 EST Northrop Grumman awarded $405.71M Air Force task order - Northrop Grumman has been awarded a $405.71M cost-plus-fixed-fee task order for engineering services. This task order provides for full spectrum lifecycle engineering, technical, and operational support for intelligence activities at Department of Defense and intelligence community customer centers and satellite locations. Work will be performed in Rome, New York, and is expected to be completed by October 2027. This award was the result of a competitive acquisition, and two offers were received. FY23 research, development, test and evaluation funds in the amount of $510,000; FY23 Air Force procurement funds in the amount of $75,000; and FY23 operations and maintenance funds in the amount of $410,000 are being obligated at the time of award. Air Force Research Laboratory is the contracting activity.

17:06 EST MEI Pharma announces realignment of clinical development efforts - MEI Pharma announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344. Following completion of the workforce reductions, MEI expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operations through clinical data milestones for both voruciclib and ME-344. The company further announced that it has engaged Torreya Partners as financial advisor to help explore additional strategic opportunities.

17:05 EST BellRing Brands announces new $50M share repurchase plan - BellRing Brands announced its Board of Directors has approved a new $50M share repurchase authorization, with share repurchases under the new authorization beginning on December 5. As of December 5, BellRing had repurchased approximately $45M under its previous $50M share repurchase authorization.

17:03 EST The Hanover raises quarterly dividend to 81c per share - Payable December 30 to shareholders of record at the close of business on December 15.

16:56 EST FVCbank names Bruce Gemmill chief marketing officer - FVCbank announced the addition of Bruce Gemmill to its team of banking leaders. Gemmill's extensive executive and marketing experience position him well for his new role at FVCbank as Senior Vice President / Chief Marketing Officer, the company said. "Having Bruce join our team of great bankers makes us an even stronger bank," said FVCbank's President, Patricia Ferrick. "The fact that FVCbank continues to attract top talent like Bruce is a testament to the exemplary reputation our Bank enjoys. Hiring the best talent strengthens the Bank and provides the continuing momentum needed to increase market share in a very competitive banking environment."

16:39 EST InterCure announces withdrawal of class action lawsuit against it - InterCure announced the withdrawal of a class action lawsuit against it. The Regenera Lawsuit was described in the company's press release dated May 26, 2020 and in the company's most recent annual report and annual information form and it was primarily concerning a motion to certify, as a class action, a claim filed against the company, its directors and its executive officers, alleging that the company violated its obligation to publicly disclose certain events and developments which impacted the valuation of Regenera Pharma. On December 2, the Tel Aviv District Court approved a consent motion to withdraw the Regenera Lawsuit, without any payment to the plaintiff from the Company.

16:35 EST Renren announces update on special cash distribution - Renren announced an increase in the per share amount to be paid in the special cash distribution, that was announced on November 3, 2022, relating to the settlement contemplated by the Stipulation of Settlement, dated as of October 7, 2021 and as amended on May 27, 2022. The amount of the special cash distribution was previously announced to be 70.13c per Renren Class A ordinary share, or $31.5585 per Renren American Depositary Share. Each one ADS currently represents 45 Renren Class A ordinary shares. The special distribution amount, in each case, is prior to the deduction of applicable taxes, fees, and expenses. As a result of interest earned on the settlement account, more funds will be available for distribution from the settlement account on a pro-rata basis, and the amount of the special cash distribution will now be 70.26c per Renren Class A ordinary share, or $31.6170 per Renren ADS; in each case, prior to deduction of applicable taxes, fees and expenses. The special cash distribution is still expected to be paid on December 21, 2022. Due bill period will run from November 18 to December 21.

16:34 EST Hepion granted 180-day extension by Nasdaq to meet minimum bid requirement - Hepion Pharmaceuticals announced that is has received written notification from the Listing Qualifications Department of The Nasdaq Stock Marke granting the Company's request for a 180-day extension to regain compliance under the Nasdaq Listing Rule 5550(a)(2). The Company now has until May 30 to meet the requirement. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share under Rule 5550(a)(2) on June 3 and was given until November 30 to regain compliance. The Company will continue to monitor its bid price of its common stock.

16:32 EST Checkpoint Therapeutics to effect 1-for-10 reverse stock split - Checkpoint Therapeutics announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock. Checkpoint expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on December 6. The reverse stock split was approved on November 3 by Checkpoint's board of directors and stockholders representing approximately 58% of the voting power of Checkpoint's outstanding capital stock. The reverse stock split is intended to improve the marketability and liquidity of Checkpoint's common stock and to remain in compliance with Nasdaq's continued listing requirements.

16:31 EST Installed Building Products acquires Orr Industries - Installed Building Products "announced the acquisition of Orr Industries, LLC. Established in 2012, Orr has locations near Scranton, PA with services in Pennsylvania and New York. Orr primarily installs spray foam and fiberglass insulation in residential and commercial projects and offers fireproofing and waterproofing services for commercial structures as well." CEO Jeff Edwards states: "With approximately $10 million of annual revenue, Orr expands our presence in Pennsylvania."

16:25 EST GitLab jumps almost 14% after Q3 report, guidance beat expectations - Shares of software for the software development lifecycle in the United States, Europe, and the Asia Pacific, GitLab, are up approximately 14% or $5.33 per share, in after market trade, to almost $44 per share, after the company's quarterly report and guidance beat expectations.

16:19 EST Natural Alternatives International raises share repurchase plan by $1M - Natural Alternatives International announced its Board of Directors authorized a $1M increase to its stock repurchase plan bringing the total plan authorized repurchase amount to $19M. "To date, we have purchased 2.1 million shares under this repurchase plan and after this increase we will have $1.2 million available for future stock repurchases under the plan."

16:18 EST Liquidia enters Treprostinil Injection collaboration with Sandoz, Mainbridge - Liquidia announced a collaboration with Sandoz and Mainbridge Health Partners to support the development of a new subcutaneous pump for infusion of Treprostinil Injection, a generic form of Remodulin, for which Liquidia has the exclusive rights to promote and commercialize with Sandoz. To enable the collaboration, Sandoz and Liquidia will enter into a joint agreement with Mainbridge. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables. The parties anticipate submitting a 510(k) in 2023 for FDA clearance. Sandoz and Liquidia will split equally the development costs. In connection with the execution of the Pump Agreement, Liquidia and Sandoz also agreed to extend their promotion agreement for Treprostinil Injection by another five years until December 31, 2032.

16:16 EST Braemar Hotels & Resorts reports preliminary portfolio occupancy 64% for Nov. - Braemar Hotels & Resorts reported preliminary portfolio occupancy of approximately 64% for the month of November with an average daily rate of approximately $394 resulting in RevPAR of approximately $253. This RevPAR reflects an approximate increase of 5% versus November 2021 and an approximate increase of 15% compared to November 2019. Additionally, for the month of October, preliminary portfolio occupancy was approximately 73% with an ADR of approximately $382 resulting in RevPAR of approximately $280. This RevPAR reflects an approximate increase of 25% versus October 2021 and an approximate increase of 14% compared to October 2019. The preliminary operating information discussed above assumes the 15 hotel properties owned and included in the company's operations at November 30, were owned as of the beginning of 2019.

16:15 EST Gibraltar Industries says COO Burns to depart from position - In a regulatory filing, Gibraltar Industries disclosed that on December 2, the company and Patrick Burns, the company's Chief Operating Officer, mutually agreed that Burns will depart from his position, effective December 30. "Following such date, the responsibilities of Chief Operating Officer will be reallocated among members of the company's existing management team," the filing stated.

16:13 EST MediWound to effect 1-for-7 reverse share split - MediWound announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares. Subject to the company's satisfaction of Nasdaq Operations notice requirements, the scheduled effective date is December 20, with trading on a reverse split-adjusted basis to begin at market open on that day. Trading of the company's ordinary shares will continue on the Nasdaq Global Market under the symbol (MDWD), but the shares will trade under the new CUSIP number, M68830112. In the event of a delay in the effective date, the company will update the public via a subsequent press release.

16:08 EST Minority Equality Opportunities extends deadline to complete combination - Minority Equality Opportunities Acquisition announced that, at a special meeting of its stockholders held on November 29, its stockholders had approved an amendment to its amended and restated certificate of incorporation to extend the date by which the company must consummate its initial business combination from November 30, 2022 up to six one-month extensions to May 30, 2023, or such earlier date as determined by the company's board of directors. In connection with each one-month extension, funds in the amount of $83,333.33 must be deposited into the company's trust account, for an aggregate deposit for the full six month extension period of $500,000. On November 30, $83,333.33 was deposited into the company's trust account to extend the period by which the company must consummate its initial business combination for the first of such one-month extensions. The extension provides the company with additional time to complete its proposed business combination with Digerati Technologies, Inc. pursuant to the Business Combination Agreement dated as of August 30 between the company and Digerati Technologies.

16:06 EST SS&C acquires Complete Financial Ops, Inc., terms not disclosed - SS&C Technologies announced it has acquired Complete Financial Ops, Inc. Fund Services, a Colorado-based fund administration firm. CFO Fund Services delivers tailored fund administration to private equity funds and family offices. Terms of the all-cash deal were not disclosed.

16:02 EST Bit Digital announces November production update - Corporate Highlights for November: In November, the company earned 144.1 bitcoins, a 5% decrease compared to the prior month. The decline in production was driven by an increase in network difficulty. Treasury holdings of BTC and ETH were 950.3 and 7,064.7 with a fair market value of approximately $16.3M and $9.2M, respectively, on November 30. The BTC equivalent of digital asset holdings as of November 30 was approximately 1,679.9. The company owned 38,593 bitcoin miners and 730 Ethereum miners as of November 30, with an estimated maximum total hash rate of 2.7 Exahash and 0.3 Terahash, respectively. 39% of the company's bitcoin mining fleet, or 14,978 bitcoin miners representing 1.40 EH/s, was actively hashing in North America as of November 30.

15:04 EST Sorrento presents Phase 2 results on PD-L1 checkpoint inhibitor IMC-001 - Sorrento Therapeutics announced the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento. The Phase II NK/T-cell lymphoma study was selected for an oral presentation at the Asian Congress of the European Society for Medical Oncology in Singapore on December 4, the company reported. "The clinical data demonstrated that in patients with heavily treated NK/T-cell lymphoma, 6 of 10 evaluable patients, or 60%, not only achieved an objective response, but all 6 patients with an objective response also achieved a complete remission with IMC-001. Additionally, 4 of these 6 patients stayed on treatment for over a year, which provides encouraging indication of long-term IMC-001 treatment safety and durable efficacy," the company reported. Henry Ji, Ph.D., CEO of Sorrento, commented, "We expect to leverage these data to create momentum to secure additional partnership and co-development opportunities for IMC-001 in regions with a high incidence of NK/T-cell lymphoma, such as China, as well as in other indications."

14:41 EST J&J says 'it does not intent to make offer' for Horizon Therapeutics - Johnson & Johnson (JNJ) says it has "no intention to bid statement for Horizon Therapeutics" (HZNP). According to a statement by the company, "Further to the announcement by Horizon on November 29, 2022, Janssen Global Services, confirmed today that it does not intend to make an offer for Horizon. Accordingly, the company will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules."

13:03 EST Winc Inc trading halted, news pending

12:50 EST Arcimoto trading halted, volatility trading pause

12:36 EST Meta expands age verification test to Facebook Dating in U.S. - Meta said it is expanding its age verification test to Facebook Dating in the U.S." We require people to be at least 18 years old in order to sign up for and access Facebook Dating, and age verification tools will help verify that only adults are using the service and help prevent minors from accessing it," the company said in a blog post. "We're also continuing our partnership with Yoti, a company that specializes in online age verification, so that people have more than one option to choose from to verify their age." Reference Link

12:18 EST User reports indicate problems at Meta's Facebook, Downdetector says - Reference Link

12:06 EST CBIZ appoints Elizabeth Newman as CAO, CHRO - CBIZ has named Elizabeth Newman to assume the dual role of Chief Administrative Officer and Chief Human Resources Officer effective December 1, 2022. Newman, who has served as Interim CHRO since September, will provide oversight for the Company's administrative functions and will lead Human Resources for all aspects of the business including cross-functional strategic projects and organizational transformation. In addition to her responsibilities as Interim CHRO, Newman also served as Chief of Staff and will continue her role on the Executive Leadership Team.

12:00 EST Miniso falls -9.3% - Miniso is down -9.3%, or -$1.11 to $10.85.

12:00 EST GreenTree Hospitality rises 10.4% - GreenTree Hospitality is up 10.4%, or 34c to $3.60.

12:00 EST ProShares UltraShort Bloomberg Natural Gas rises 16.1% - ProShares UltraShort Bloomberg Natural Gas is up 16.1%, or $2.74 to $19.81.

11:02 EST Rivian Automotive enters wind energy deal with Apex Clean Energy - Rivian and Apex Clean Energy announced the signing of a power purchase agreement for 50 megawatts of electricity from the renewable energy company's proposed Goose Creek Wind farm in Piatt County, Illinois. As Rivian's first large-scale procurement, the agreement supports the company's long-term vision of enabling high-impact renewable energy projects that reduce its carbon footprint while also benefiting customers, communities, and the electrical grid. This purchase, along with other renewable sourcing and on-site generation, will allow Rivian to power as much as 75% of its Normal, Illinois, plant operations with carbon-free energy on an hourly basis. The PPA will also contribute to the company's commitment to power its Rivian Adventure Network and Waypoints charging with 100% renewable energy.

10:30 EST Axalta Coating enters multiyear agreement with Steer Automotive Group - Axalta signed a multi-year agreement with Steer Automotive Group. Under the terms of the agreement, Axalta is the single preferred paint partner, supplying its premium refinish brand Standox to Steer Automotive Group's 57 UK sites.

10:01 EST America's Car-Mart to acquire Taylor Auto Credit, terms not disclosed - America's Car-Mart announced that its subsidiary, America's Car Mart, Inc., has entered into a definitive agreement to purchase the ongoing dealership assets of Credit-Line, Incorporated and Loanco., Inc., both Texas corporations doing business as Taylor Auto Credit. As a result, the company will be entering a new market in Taylor, Texas. The existing finance receivables will be excluded from the transaction and will be collected by the seller. The company expects to close the agreement prior to December 31, 2022.

10:00 EST United States Natural Gas Fund falls -7.2% - United States Natural Gas Fund is down -7.2%, or -$1.37 to $17.71.

10:00 EST Amprius Technologies falls -12.9% - Amprius Technologies is down -12.9%, or -$1.33 to $8.97.

10:00 EST ProShares UltraShort Bloomberg Natural Gas rises 14.4% - ProShares UltraShort Bloomberg Natural Gas is up 14.4%, or $2.46 to $19.53.

09:58 EST Verve Therapeutics sinks 21% after FDA requests more clinical data

09:57 EST Verve Therapeutics receives information from FDA regarding clinical hold - Verve Therapeutics disclosed that on December 2, it received a clinical hold letter from the Food and Drug Administration that outlined the information required to resolve the clinical hold, including additional preclinical data relating to: potency differences between human and non-human cells, risks of germline editing, and off-target analyses in non-hepatocyte cell types. The FDA also requested available clinical data from the ongoing heart-1 trial. In addition, the FDA has requested that Verve modify the trial protocol in the United States to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants. Verve intends to submit a response "as expeditiously as possible." It added, "Verve continues to enroll patients in the heart-1 clinical trial in New Zealand and the United Kingdom and plans to report initial safety and pharmacodynamic data from the dose-escalation portion of the heart-1 trial in the second half of 2023." As previously announced, Verve was informed on November 4 by the FDA that its IND application to conduct a clinical trial in the United States evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia, a prevalent and potentially life-threatening subtype of atherosclerotic cardiovascular disease, had been placed on hold.

09:47 EST Amprius Technologies falls -10.5% - Amprius Technologies is down -10.5%, or -$1.08 to $9.23.

09:47 EST Cato Corp. falls -13.5% - Cato Corp. is down -13.5%, or -$1.36 to $8.73.

09:47 EST Agiliti rises 12.7% - Agiliti is up 12.7%, or $2.21 to $19.64.

09:43 EST Sunlands Technology Group - ADR trading resumes

09:38 EST Sunlands Technology Group - ADR trading halted, volatility trading pause

09:28 EST G Medical Innovations receives two U.S. patents for monitoring products - G Medical Innovations Holdings announced that it received two granted patents from the United States Patent and Trademark office for its monitoring products marketed in the U.S. market. The granted patents are: METHOD, DEVICE AND SYSTEM FOR NON-INVESIVELY MONITORING PHYSIOLOGICAL PARAMETERS: This patent integrates sensing mechanism that allows the monitoring system to analyze the sensing condition prior to performing and during continuous monitoring of physiological signals from the body. This allows higher and more accurate sensing that: results in reducing false positive reading including false alarms. JACKET FOR MEDICAL MODULE The patent harness the traditionally use smartphone flip case concept and convert it to a medical case allowing consumers and patients to carry their Smartphones and monitoring device together, ensuring the ability of monitoring vital signs and other parameters, Anywhere, Anytime.

09:26 EST Concord Acquisition Corp trading halted, news pending

09:23 EST Diana Shipping announces delivery of m/v DSI Pegasus - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/v DSI Pegasus, a 2015 built Ultramax dry bulk vessel of 60,508 dwt. The vessel is one of nine modern Ultramax dry bulk vessels that the Company entered into an agreement to purchase in August 2022.

09:18 EST Performance Shipping announces delivery of M/T P. Monterey - Performance Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the M/T P. Monterey, a 2011-built Aframax tanker vessel of 105,525 dwt that the Company entered into an agreement to purchase in September 2022. As previously announced, the M/T P. Monterey was acquired for a total purchase price of $35 million and partially financed through the recently announced term loan facility with Piraeus Bank S.A. Following the delivery, as previously disclosed, the vessel will commence a time charter contract with ST Shipping & Transport Pte Ltd., a wholly-owned subsidiary of Glencore, at a daily rate of $32,000 per day for a period of twenty-four months +/- 45 days at the option of the charterer. The M/T P. Monterey is equipped with a ballast water treatment system, and its next scheduled special survey is not due until 2026. The vessel is the third vessel delivered to the Company during the course of this year.

09:15 EST McCormick names Sarah Piper as Chief Human Relations Officer - McCormick & Company (MKC) announced the appointment of Sarah Piper to Chief Human Relations Officer, effective December 1. Piper has become a member of McCormick's Management Committee. Piper joined McCormick in 2008 as a Human Relations Manager and subsequently held the roles of Director, Human Relations, and Vice President, Human Relations for the Consumer Products Division. Prior to joining McCormick, Piper held a variety of Human Resources roles at Pfizer (PFE) and KPMG in the United States and Canada.

09:12 EST Delcath Systems announces results from study of PHP procedure with CHEMOSAT - Delcath Systems announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure with CHEMOSAT for the treatment of either inoperable intrahepatic cholangiocarinomas or extrahepatic cholangiocarinoma with liver metastases. The article, New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option by Dr. Cornelia L. A. Dewald, et al, was a retrospective analysis of 17 patients who underwent a total of 42 PHP procedures between October 2014 and September 2020 at the Hannover Medical School in Germany. The aim of the retrospective, monocentric study was to analyze PHP as a palliative treatment for unresectable liver dominant CCA. 16 of the 17 patients were evaluable for response as one patient died without follow-up imaging 13 weeks after the first PHP with no identifiable relationship to the PHP treatment. After the first PHP, one patient presented with a complete response. Three patients had a partial response in the first follow-up exam and seven patients presented with stable disease. Five patients had progressive disease, one of which was limited to extrahepatic progression only. In total, in 17 treated patients an overall response rate of 25% and a disease control rate of 75% was achieved. Two patients with PR, six patients with SD and the patient with PD limited to extrahepatic progression received further PHP treatments. In the subsequent follow-up exams, the overall best therapy response in these patients was PR in 78% and SD in 22%. One patient was treated in total with 8 PHP treatments within 30 months. The median progression free survival was 3.5 months with a similar median hepatic PFS of 3.6 months. Calculated from first diagnosis of iCCA, the median survival was 27.6 months. From first PHP, a median survival of 9.9 months was observed, with a 1-year survival rate of 41%. For context, the authors noted that for inoperable CCA, the treatment options are limited and a median survival of 2.5 - 6 months is to be expected, which can be extended to approximately 12 months under first-line chemotherapy with gemcitabine and cisplatin. In this study all patients were previously treated with at least systemic therapy and the authors note that the results of their analyses confirms the potential for survival extension by PHP treatment even after the exhaustion of systemic therapies. No significant complications occurred during the PHP treatments. Significant, but transient and clinically manageable, hemotoxicity was reported with grade 3/4 thrombocytopenia after 50%, anemia after 26% and leukopenia after 21% of the PHP treatments. There were no PHP-related deaths. The authors stated that the toxicity rates were consistent both with previously published PHP values and with first-line systemic therapy with gemcitabine/cisplatin in CCA. The authors highlighted the increasing importance of locoregional forms of therapy in the treatment of CCA and that the new edition of the German S3 cancer guideline "Diagnostics and Therapy of Hepatocellular Carcinoma and Biliary Carcinomas" now includes PHP with melphalan for the treatment of inoperable iCCA or eCCA liver metastases. Based on the results of this study the authors concluded that for patients with inoperable, treatment-refractory iCCA and CCA liver metastases PHP is an effective and safe treatment option that has the potential to prolong life in a palliative setting.

09:07 EST Agora partners with HTC, Magic Leap ahead of Immerse Global Summit - Agora announced it will team with partners HTC, a global innovator in smart mobile devices and technology, and Magic Leap, an enterprise-grade AR technologies leader. The partnerships will showcase the power of real-time engagement and XR innovations across all sectors in Augmented Reality in education, industrial Internet of Things, telehealth and more. These collaborations will be showcased at this year's Immerse Global Summit, set to take place from December 5 to 7 at the Fontainebleau Hotel in Miami, Florida. In Miami, Agora will demo the offerings from their partnerships with HTC and Magic Leap. "Agora is uniquely positioned to deliver cutting-edge technologies with HTC and Magic Leap," said Tony Zhao, Agora's CEO. "We're always looking for ways to empower our digital content and provide scalable developer-friendly interoperable platforms to enterprises using our easy-to-embed SDKs, especially in the metaverse. This partnership and seamless collaboration is the future of the interactive AR/VR space across all devices, platforms, and frameworks."

09:06 EST Merrimack board extends Section 382 net operating loss rights plan - Merrimack announced that its board of directors has extended the Section 382 net operating loss rights plan that was adopted in 2019. The plan is designed to protect the company's ability to use its valuable net operating loss carryforwards and certain other valuable tax attributes. The extension is effective through December 2, 2025 but would terminate at the time of the company's 2023 annual meeting if the extension is not approved by the company's shareholders at that annual meeting.

09:06 EST Ezcorp increases investment in Florida and Caribbean - Ezcorp announced two investments that highlight its continuing initiatives to expand its geographic footprint and broaden its pawnbroking offerings. The Company recently increased its investment in Founders One a private company that owns a majority interest in Simple Management Group, SMG . This increased investment comprised of a $15M preferred equity contribution and a $15M loan, along with other third-party financing secured by SMG, was used by SMG to acquire 100% of the outstanding capital stock of FFI Holdings, which owns 52 pawnbroking stores in Florida and Puerto Rico operating under the "La Familia" or "Family Financial" brand. That acquisition was completed on December 2 and with it, SMG now owns and operates a total of 73 pawnbroking stores . Additional information about the Company's increased investment in Founders One can be found in its Current Report on Form 8-K, dated December 2 filed with the Securities and Exchange Commission. EZCORP also recently acquired a luxury pawnbroking business in Las Vegas operating under the name "Max Pawn" and established a joint venture with Michael Mack, the former owner of Max Pawn. The joint venture will focus on the luxury goods space in Las Vegas and other selected markets across the U.S. In connection with the acquisition, Mr. Mack has joined EZCORP to lead the Company's new Luxury Pawn Division. "We continue to execute on exciting inorganic strategic opportunities to expand our core pawnbroking business in both existing and new geographic regions. Our increased investment in Founders One gives us enhanced exposure to the strategically important Caribbean region along with increased exposure to the Florida market," said Lachie Given, Chief Executive Officer of EZCORP.

09:05 EST Centene completes divestiture of Magellan Rx to Prime Therapeutics - Centene announced that it has successfully completed the previously announced divestiture of Magellan Rx to Prime Therapeutics LLC. Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health.

09:04 EST LPL Financial: Financial House team joins RIA, custodial platforms - LPL Financial announced that the team at Financial House has joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported having served approximately $650 million in advisory, brokerage and retirement plan assets, and join LPL from Lincoln Financial.

09:03 EST ElectraMeccanica CEO Kevin Pavlov resigns, Susan Docherty succeeds - ElectraMeccanica announced leadership and operating changes in order to accelerate its transition to onshore manufacturing and commercialization of its unique horizontal market. Susan Docherty, a CEO, executive and board member with three-plus decades of experience driving growth, transforming brands and defining markets, including over 25 years at General Motors, assumes both the CEO and interim COO roles effective immediately. Kevin Pavlov and Joe Mitchell, respectively the outgoing CEO and COO, have resigned to pursue other opportunities. In connection with this leadership change, the company also announced that it will officially commission its Mesa, Arizona manufacturing facility on December 12 and hold its first-ever investor day on February 15, 2023.

09:03 EST Health Catalyst announces multi-year contract with Carle Health - Health Catalyst announced an expansive, multi-year contract with Carle Health, an integrated health system based in Urbana, Illinois that includes five hospitals, multi-specialty physician group practices with more than 1,000 doctors and advanced practice providers, and Health Alliance Medical Plans, deepening its relationship with Health Catalyst to further advance Carle's innovative analytics capabilities system-wide. Beginning in January 2023, Carle Health Clinical and Business Intelligence team members will transfer employment to Health Catalyst, where they will have the opportunity to grow professionally within Health Catalyst's enhanced environment of data literacy and technology resources. As Health Catalyst employees, transitioned team members will constitute a specialized, expert team that will continue to provide analytics support and innovation to the Carle Health system.

09:03 EST Hepion announces early completion of enrollment in Phase 2 ALTITUDE-NASH trial - Hepion Pharmaceuticals announced that it has completed enrollment of 60 NASH stage 3 subjects in the Phase 2 ALTITUDE-NASH clinical trial. The trial is being conducted in collaboration with HepQuant and Summit Clinical Research, at 20 sites within Summit's Integrated Research Organization. ALTITUDE-NASH is a Phase 2, randomized, multi-center, open-label study designed to evaluate the safety and efficacy of rencofilstat on hepatic function and numerous NASH biomarkers after four months of dosing. Subjects are randomized to receive a once daily, oral dose of 75, 150, or 225 mg rencofilstat soft gelatin capsules over a period of four months. The HepQuant 'SHUNT' test, a measure of hepatic function, will be performed at baseline, and changes in the Disease Severity Index score relative to baseline measurements will be determined at days 60 and 120. Other NASH biomarkers will be collected throughout the study duration. Todd Hobbs, MD, Hepion's Chief Medical Officer, added, "Having initiated dosing in the larger and longer Phase 2b 'ASCEND-NASH' trial, Hepion's priority is to use the ALTITUDE-NASH trial to understand the impact of three different doses of rencofilstat on NASH subjects, based on hepatic function and biomarkers. Modelling these results over the course of four months should allow us to better predict the outcome of the one-year, biopsy-confirmed ASCEND-NASH trial."

09:00 EST Salisbury Bancorp trading resumes

08:49 EST Farmers National Banc, Emclaire Financial get regulatory approval for merger - Farmers National Banc (FMNB) and Emclaire Financial (EMCF), the holding company for The Farmers National Bank of Emlenton jointly announced that they have received regulatory approvals, including approval from the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency, necessary to complete the proposed merger of Emclaire Financial Corp. with and into FMNB Merger Subsidiary V a newly-formed wholly-owned subsidiary of Farmers pursuant to the Agreement and Plan of Merger dated as of March 23, 2023 by and between Farmers and Emclaire and the related merger of Emlenton Bank with and into Farmers National Bank. The Merger is expected to be completed in January .

08:43 EST TeraWulf mines 134 Bitcoin in November - TeraWulf provided an unaudited monthly production and operations update for November. Self-mined 134 Bitcoin in November, an increase of approximately 13% as compared to October production of 119 Bitcoin. Cost of power declined sequentially in November to approximately $0.035/kWh as compared to approximately $0.058/kWh in October and approximately $0.089/kWh in Q3. Remains on track to realize blended cost of power of approximately $0.035/kWh, comprised of approximately $0.045/kWh at the Lake Mariner facility and $0.02/kWh fixed at the Nautilus Cryptomine facility. Deployed fleet of 17,500 miners achieving hash rate capacity of 2.0 EH/s as of November 30, 2022. Average operating hash rate of 1.9 EH/s in November 2022, an increase of nearly 20% as compared to October's average operating hash rate of 1.6 EH/s.

08:42 EST Capstone continues to grow in EaaS market with Texas cryptocurrency firm deal - Capstone Green Energy continues to grow in the Energy as a Service EaaS market with a new 2-year rental agreement for a cryptocurrency data mining operation in West Texas. The contract was secured by Lone Star Power Solutions, Capstone's exclusive distributor in Texas, Arizona, and the Gulf States and is expected to be commissioned in mid-December. The customer is currently evaluating an additional 1MW system to be deployed in early 2023.

08:42 EST Primavera Capital Acquisition, Lanvin Group provide update on combination - Lanvin Group and Primavera Capital Acquisition Corporation announced that South Korea-headquartered fashion retailer, Handsome Corporation, will join the Group's alliance of strategic investors. Founded in 1987, Handsome manages 1,389 stores across the world and a portfolio of over 30 brands generating close to $1.1B in annual revenue in 2021. It is an affiliate of South Korean retail conglomerate Hyundai Department Store Group. Handsome has been the exclusive distributor of Lanvin, one of the Group's portfolio brands, in South Korea since 2007. It has partnered with the Group in successfully cultivating the brand, with more than 60 points of sales in the South Korean market. Separately, on December 2, 2022, the Group, PCAC and relevant parties entered into an amendment to the business combination agreement to remove the closing condition in relation to the minimum amount of cash of at least $350M. Additionally, on December 2, 2022, the Sponsor entered into a letter agreement with PCAC and Lanvin Group, among other parties, pursuant to which the Sponsor irrevocably surrendered, subject to the closing of the Business Combination and effective immediately prior to the consummation of the initial merger, 6,014,375 Class B ordinary shares of PCAC to PCAC for nil consideration, which shares shall be cancelled by PCAC immediately upon the surrender thereof, such that after giving effect to the share surrender, the number of Class B ordinary shares of PCAC held by the Sponsor shall be 5,000,000. The closing of the Business Combination and the first day of trading on the NYSE under the ticker symbol "LANV" is expected before the end of this year, subject to customary closing conditions, including the approval of PCAC's shareholders and the approval for the listing of securities of Lanvin Group Holdings Limited on the NYSE.

08:40 EST Ekso Bionics announces acquisition of business unit from Parker Hannifin - Ekso Bionics (EKSO) announced the acquisition of the Human Motion and Control, HMC, Business Unit from Parker Hannifin Corporation (PH), a global leader in motion and control technologies. The acquisition includes the Indego lower limb exoskeleton line of products as well as the planned development of robotic assisted orthotic and prosthetic devices. This complementary acquisition expands Ekso's product offering across the continuum of care to home and community use markets, grows Ekso's product pipeline and adds strategic relationships with key commercial and research partners. "Indego is one of the most advanced and broadest range of powered and intelligent devices for home use, which represents a strategic fit for Ekso," said Scott Davis, Chief Executive Officer of Ekso Bionics. "This acquisition is expected to contribute immediately to our top-line results, improve operating efficiencies and establish Ekso as a leader in lower extremity robotics. Moving forward, we plan to continue exploring future growth opportunities that align with our strategy." Ekso Bionics acquired all of Parker's HMC global business assets in the U.S. and Europe for an aggregate purchase price of $10 million. Ekso paid $5 million at closing and delivered a $5 million subordinated, unsecured zero coupon note payable quarterly over four years, commencing December 31, 2023. In connection with the acquisition, Sherman resigned as the Company's Chief Executive Officer, and the Ekso Bionics Board of Directors appointed Davis as Chief Executive Officer, each effective immediately. Davis has served as the Company's President and Chief Operating Officer since January 2022. Sherman will continue to serve as Chairman of the Board and will begin serving as Executive Chair of the Company.

08:39 EST Dermata Therapeutics announces results from DMT310 Phase 2 trial - Dermata Therapeutics announced topline results from its Phase 2 trial of once-weekly topical application of DMT310 for the treatment of moderate-to-severe rosacea. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, with positive Phase 2 data in moderate-to-severe acne and Phase 1b data in mild-to-moderate psoriasis. "While the final data were not what we had hoped for, we were encouraged to see a 44% reduction in inflammatory lesion counts after just 4 treatments with DMT310, which mirrors the 45% reduction in inflammatory lesion counts we saw in our DMT310 Phase 2b acne study," stated Christopher Nardo Ph.D., Dermata's Chief Development Officer. "We believe the above average dropout rate of 23% for patients treated with DMT310 seen in this rosacea study, versus 13% seen in the Phase 2b acne study, could explain the reduced treatment effect of DMT310 at Week 12. Rosacea is a complicated skin disease that affects patients with sensitive skin and the disease waxes and wanes with environmental and physiological exposures. Some patients did achieve a meaningful change in their rosacea with 36% of DMT310 patients meeting the criteria for a responder on the Investigators Global Assessment scale at Week 12. However, DMT310 was not able to statistically separate from placebo with 23% of placebo patients meeting the criteria as a responder at Week 12," continued Dr. Nardo. "A treatment responder is defined as an IGA grade of 'clear' or 'almost clear' and at least a 2-grade improvement from baseline. Lastly, we want to thank the patients and investigators who participated in this study."

08:38 EST ToughBuilt launches line of long-handle garden, landscaping tools - ToughBuilt Industries announced the launch of the Company's new line of Long Handle Garden and Landscaping Tools. Beginning with 11 out of about 150 SKUs, the new line includes many innovative improvements. This new product line joins the Company's existing line of hand tools and will be made available for purchase through a leading US home improvement retailer and across ToughBuilt's growing strategic networks of North American and global trade partners and buying groups, servicing over 15,500 storefronts and online portals worldwide.

08:37 EST Icanic Brands changes names to Leef Brands - Icanic Brands Company is pleased to announce that the Canadian Securities Exchange has granted the Company approval to change its corporate name to Leef Brands. In connection with the name change, the Company's common shares will trade under the new trading symbol, "LEEF" as of December 7th, 2022. The Company's new CUSIP is 52426X104 and its new ISIN is CA52426X1042. In conjunction with the Company's name change, the Company is also pleased to announce that it continues to make significant progress towards the growth and market penetration of its internal brands. To date, the Company has derived approximately 80% of its revenue by providing its products and services to the largest cannabis brands in California. Going forward, while the Company will continue to provide these white labeling services, it will aim to significantly improve its margins by increasingly utilizing its robust supply chain and enhanced manufacturing capabilities toward its own internally branded products. This will be furthered through a targeted M&A approach that will focus on the acquisition of brands that will greatly benefit from the Leef in-house manufacturing capabilities. The Company's long-term objective is for approximately 50% of its revenue to be derived from a portfolio of in-house brands. In addition to focusing on its internal brands, the Company is also intent on leveraging its manufacturing skill set and brand recognition to enter new markets by partnering with out of state manufacturing companies through licensing agreements or by way of M&A. This strategy will allow Leef to upgrade the processes and procedures of partnering companies, while also enabling Leef to launch its brand portfolio and other clients' brands into these new markets.

08:37 EST Frontdoor CFO Brian Turcotte to step down, Jessica Ross to succeed - Frontdoor (FTDR) announced that it has appointed Jessica Ross as senior VP and CFO, replacing Brian Turcotte, who will step down on December 30. To ensure a leadership transition, Turcotte will remain with the company through March 31, 2023 as an advisor to the CEO. Ross brings over two decades of cross-industry finance and digital transformation experience scaling companies across multiple stages of growth. She joins Frontdoor from Salesforce (CRM) where she currently serves as executive VP, enterprise strategy and operational excellence.

08:36 EST Alexandria Real Estate raises quarterly dividend to $1.21 from $1.18 per share - The dividend is payable on January 13, 2023, to shareholders of record on December 30, 2022.

08:35 EST Kore Group forms go to market alliance with Google Cloud - Kore (KORE) announced that it has established a go to market alliance with Google Cloud (GOOG, GOOGL) to bring IoT capabilities to global businesses. This multi-year alliance will help enterprises create robust IoT solutions that leverage Google Cloud infrastructure and capabilities, as well as Kore's IoT Solutions. The alliance brings together Kore's expertise of simplifying the complexities of IoT deployment with a rich set of 'one stop shop' services and the ability to orchestrate the IoT ecosystem of devices, global connectivity and services, paired with Google Cloud's data and analytics excellence for optimal business outcomes.

08:34 EST Duck Creek Technologies announces Copart has joined its partner ecosystem - Duck Creek Technologies (DCT) announced that Copart (CPRT) has joined its rapidly growing partner ecosystem and that a feature-rich integration for the Copart Assignment Processing Service is now available to its customers on the Duck Creek Content Exchange. Copart is a global leader in online vehicle auctions and a premier platform for the resale and remarketing of vehicles from 11 countries to buyers around the world. "Our integration with Copart further demonstrates Duck Creek's commitment to providing an end-to-end partner ecosystem for vehicle insurers," said Robert Fletcher, Sr. Partner Manager at Duck Creek Technologies. "Through our partnerships and integrations with both leading technology startups and well-established global innovators like Copart, our goal is to offer a seamless process to both our carrier customers and their policyholders that improves the claims experience overall."

08:33 EST Inozyme announces peer-review publication on prevalence of ENPP1 deficiency - Inozyme Pharma announced the publication of an article titled "Estimation of ENPP1 Deficiency Genetic Prevalence Using a Comprehensive Literature Review and Population Databases" in the Orphanet Journal of Rare Diseases. Leading disease experts Carlos Ferreira, M.D., of the National Institutes of Health and Frank Rutsch, M.D., of Munster University Children's Hospital, together with Genomenon, an AI-driven genomics company, analyzed the latest genomics data and found the estimated prevalence of ENPP1 Deficiency to be 1 in 64,000 pregnancies, more than tripling the prior estimate. "Our medical field team's disease awareness, education, and patient identification efforts suggested that the number of patients with ENPP1 Deficiency has been vastly underestimated. These new data provide an independent and thorough calculation supporting our observations and highlight the urgent need for a therapeutic option," said Axel Bolte, MSc, MBA, Inozyme's co-founder, president and chief executive officer.

08:31 EST Hertz announces settlement agreements regarding past legal claims - Hertz announced the settlement of 364 pending claims relating to vehicle theft reporting, bringing resolution to more than 95% of its pending theft reporting claims. The company will pay an aggregate amount of approximately $168M by year-end to resolve these disputes. The company believes it will recover a meaningful portion of the settlement amount from its insurance carriers. Hertz does not expect the resolution of these claims to have a material impact on its capital allocation plans for the balance of 2022 and 2023.

08:25 EST Dermata Therapeutics Inc trading halted, news pending

08:17 EST NextPlat appoints Cecile Munnik as CFO, Robert Bedwell as COO - NextPlat expanded its executive leadership team with the hirings of Cecile Munnik, CPA/CA, as Chief Financial Officer and Robert Bedwell as Chief Compliance Officer. On November 14, 2022, Ms. Munnik joined the Company as its new CFO. Ms. Munnik also currently serves as the CFO of Progressive Care, a position she has held since October 2020. On November 7, 2022, Mr. Bedwell joined the Company as its new CCI. Mr. Bedwell previously served as the Director of Administrative Services of PharmCo, a wholly-owned subsidiary of Progressive Care. As a material inducement to enter into their respective employment agreements with the Company, Ms. Munnik and Mr. Bedwell each received an initial award of stock options for 50,000 shares of the Company's common stock pursuant to their respective employment agreements. The option grants were issued outside of a shareholder approved stock or option plan pursuant to the Nasdaq "inducement grant" exception. The option awards for Ms. Munnik and Mr. Bedwell each vest as follows: options for 25,000 shares are fully vested grant date; options for 10,000 additional shares will become fully vested on the first anniversary of the grant date; and options for an additional 15,000 shares will become fully vested on the second anniversary of the grant date, in each case subject to their respective continued employment with the Company.

08:15 EST Potbelly announces four additional shop development agreements - Potbelly announced it is successfully continuing to build upon its Franchise Growth Acceleration Initiative through the execution of development agreements with several existing franchisees. The agreements extend development rights with Brent Brouse, Paul Goldammer, Fabian Nelson and Mohit Kishore and Tulshi Bakar; each of which are strong operators in the Company's system. Under the agreements, Potbelly's collective footprint in these markets will be expanded with 25 new shops over the next six years. Today's announcement comes on the heels of the Company's recently signed development deals for a total of 25 additional shops in Florida and Illinois over the next eight years, resulting in a cumulative total of 50 new shops to date. "It's been a significant last couple of months for us at Potbelly - with our double-digit same-store sales growth and excellent sales to investment ratio, we're signing deals for new markets as well as reaffirming our strong relationships with existing franchisees," said Bob Wright, President and Chief Executive Officer of Potbelly. "Our model and strategy are working, and we are pleased to continue our growth story with strong operators in our Potbelly family."

08:14 EST Ensysce Biosciences completes clinical portion of PF614-MPAR-101 Part A trial - Ensysce Biosciences announced that it has completed the clinical portion of study PF614-MPAR-101 Part A, entitled 'Single-Dose Study to Evaluate the Pharmacokinetics of oxycodone and PF614, when PF614 Solution is Co-Administered with Nafamostat, as an Immediate-Release Solution and/or Extended-Release Capsule Formulations in Healthy Subjects', being conducted by Dr. Maria Bermudez MD, at Quotient Sciences, Miami Florida. MPAR is designed to prevent drug overdose by inhibiting the activation and release of opioid when more than prescribed doses are taken. PF614 is a TAAP prodrug of oxycodone designed to reduce abuse of this opioid pain medication. TAAP chemical modification inactivates the active ingredient in Ensysce's products until they are swallowed and exposed to a digestive enzyme, trypsin. PF614 requires exposure to trypsin, which safely turns 'on' the release of oxycodone. The PF614-MPAR has additional protection of an added trypsin inhibitor, nafamostat, to turn 'off' the release of oxycodone in an overdose situation. The MPAR combination technology of a TAAP prodrug and a trypsin inhibitor is the first platform that the Company expects may prevent all four common methods of opioid abuse - chewing, inhaling, injecting and oral overdose.

08:13 EST Cantaloupe acquires Three Square Market for $41M - Cantaloupe announced the completion of its acquisition of Three Square Market for $41M. 32M is a provider of software and self-service kiosk-based point of sale and payment solutions that power the micro market industry. The acquisition delivers full service capabilities to Cantaloupe's presence in the micro market industry while also immediately expanding Cantaloupe's international footprint for its full suite of products. The purchase price of $41M was funded with 90% cash and 10% stock. The stock consideration is subject to a two-year vesting schedule. Cantaloupe has funded the cash portion with $25M of debt from its existing credit facility and existing cash on hand. 32M is estimated to produce $19M of revenue with EBITDA margins of 20%+ for calendar year 2022 on a standalone basis.

08:12 EST Xwell to introduce customizable services in XpresSpa and Treat locations - XWELL will introduce fully autonomous and customizable services in select XpresSpa and Treat locations in the United States. Beginning in Q1 2023, XWELL will launch the new offerings in up to seven spas across the company's portfolio of 33 retail locations with the intent to deploy as many as 50 units across the business domestically and internationally. Guests will have the opportunity to receive automated chair massages through HydroMassage and Human Touch. The HydroMassage Lounge utilizes water to provide users a full-body massage. The Human Touch Novo XT PRO delivers fully personalized therapy through high-performance robotic massage with zero gravity capabilities and Cloud Touch acupressure to manipulate the body and stretch muscles. Guests will have the ability to control the duration, speed and strength of their massages.

08:10 EST NFL, Genius Sports expand partnership to provide video streams to Caesars - The National Football League, or NFL, and Genius Sports (GENI) announced an expansion of their partnership to connect fans with live, select NFL games through major U.S. sports betting platforms. As part of this expanded agreement and as an added benefit of its standing as an official sports betting partner and the first official casino sponsor of the NFL, Caesars Entertainment (CZR), will become the first sportsbook operator to provide its U.S. customers with live Watch & Bet video streams for select NFL games on their mobile phones or tablets via the Caesars Sportsbook app. Genius Sports will leverage its machine learning and live streaming technologies to power enhanced viewing experiences for NFL fans through Watch & Bet, and the development of its augmented live video betting products. The NFL appointed Genius Sports in April 2021 as its exclusive worldwide distributor of real-time official play-by-play statistics, proprietary Next Gen Stats data, and the League's official sports betting data feed to media companies and sportsbooks in regulated markets. This partnership included the rights for Genius Sports to distribute low latency video feeds to sportsbooks in key international markets, which has now been expanded to include the U.S. As a first of its kind in the U.S., Caesars Sportsbook will offer official data-driven in-game betting opportunities and player props alongside live video streams of NFL games to give their customers access to in-play NFL betting experience available for mobile and tablets. In addition, Caesars Sportsbook will utilize official NFL league and team marks and logos to help promote their live premium content through a Watch & Bet live wagering experience.

08:10 EST Celularity gets Halal certification of advanced cellular therapy, biz model - Celularity announced that it received Halal Certification of its business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that they have undergone rigorous assessment to determine that they are permissible or acceptable in accordance with Islamic law or Sharia. The certificates were issued under the authority of Circle H International and offer the Company the ability to serve Islamic markets globally. This announcement supports Celularity's global expansion strategy, which will ultimately include a presence in the Middle East North Africa or MENA region and a priority focus on Saudi Arabia. Celularity's CEO, Chairman and Founder, Robert J. Hariri, M.D., Ph.D., said, "Obtaining broadly inclusive Halal Certification is a critical first step and an important milestone in Celularity's plan to expand potential markets for our innovative cellular therapeutic candidates and biomaterial products. With the global Muslim population representing 28.26% of the world's population, according to Fortune Business Insights, this certification facilitates our ability to grow and expand in international markets."

08:08 EST Valens Semiconductor: JASPAR validates MIPI A-PHY specification - Valens Semiconductor announced that the Japan Automotive Software Platform and Architecture organization has formally validated the MIPI A-PHY specification for its network of Japanese OEMs and Tier 1s, including Toyota, Nissan, Honda, Mazda, and DENSO. This came after the Valens Semiconductor VA7000 A-PHY-compliant chipsets passed JASPAR's rigorous testing for Electromagnetic Compatibility, marking an important milestone for the integration of these chipsets into safety-critical Advanced Driver-Assistance Systems.

08:07 EST H2O Innovation awarded C$12.1M of new water treatment projects - H2O Innovation is pleased to announce that its Water Technologies & Services business line has recently been awarded two new water treatment projects. These projects both include the supply of ultrafiltration technology and diversify our order backlog for the current fiscal year. These new contracts, with a total value of $12.1 M, bring the WTS backlog to $55.1 M. The largest of the two projects consists of a seven-train UF system for the City of Grants Pass, in Oregon. This system is designed for a capacity of 22.5 MGD to provide drinking water for the community. H2O Innovation submitted a proposal with a higher initial capital cost but with a significantly greater long-term value to the City's ratepayers and was therefore recommended as the successful bidder over two other proposers. The project will start with an engineering phase, and the fabrication of equipment is expected to be completed in 2024. The second project involves a UF-RO system expansion for the City of Sherman, Texas, in order to bring the total capacity of the system to 14.0 MGD. The scope for this project is to add two additional UF trains to the existing five trains that H2O Innovation provided in 2018, as well as an additional RO train to expand the two trains provided in 2019. This expansion is a fast-tracked upgrade that is expected to be completed within the next 12 months.

08:07 EST Lowe's targets net-zero emissions across Scopes 1, 2 and 3 by 2050 - Lowe's announced its goal to reach net-zero emissions across the company's scope 1, 2 and 3 greenhouse gas emissions by 2050, in accordance with guidelines from the Science Based Targets initiative, the global body enabling businesses to set emissions reduction targets in line with climate science. To meet interim SBTi targets, Lowe's has also committed to decreasing its scope 1 and scope 2 emissions by 40% and reducing scope 3 emissions by 22.5% below 2021 levels by 2030. The net-zero target builds on Lowe's commitment to sustainability and recent progress, including achieving its 2025 goal of reducing scope 1 and scope 2 greenhouse gas emissions by 40% - relative to 2016 emissions levels - four years early. The company is also working to reach 50% renewable energy for Lowe's facilities by 2030, and 74% of its strategic suppliers had sustainability goals in place in 2021.

08:06 EST Yoshitsu announces business update for its duty-free shopping services - Yoshitsu provides a business update for its duty-free shopping services. With the inbound tourism recovery in Japan, the Company strives to explore the market opportunities of domestic duty-free shopping. The Company began providing pickup services since November 11, 2022, at its Urawa store and KoshigayaRyutsudanchi store in Saitama, Japan and its Hakuba store in Nagano, Japan. The Company has become the first company to offer pickup services at pharmacies in Tokyo and the first company to offer duty-free shopping service on TaxFreeOnline.jp in Nagano. Mei Kanayama, the Principal Executive Officer of Yoshitsu Co., Ltd, commented, "We are excited to see that the Japanese government opened its borders to foreign visitors, which should prompt the inbound tourism recovery in Japan. We strive to attract foreign visitors by providing TFO and pickup services at our stores, which offer them a convenient shopping experience during their stay in Japan. Looking forward, we will remain focused on providing unparalleled services and diversified selection of products at our stores. We are confident that our improved customer experience and promotion activities will attract foreign visitors and our strong capacity will meet the anticipated increased needs of foreign visitors."

08:05 EST Medtronic completes enrollment in SPHERE Per-AF Trial - Medtronic announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. FDA Investigational Device Exemption pivotal trial designed to evaluate the safety and effectiveness of the first-of-its kind Sphere-9 pulsed field and radiofrequency ablation, and high density mapping catheter with the Affera cardiac mapping and navigation platform for the treatment of persistent atrial fibrillation. The SPHERE Per-AF Trial is a global, prospective, multicenter, randomized clinical trial. Since the trial's commencement in December 2021, the trial enrolled 477 patients with persistent AF across 23 centers in the U.S. and Europe. Patients will be assessed for 12 months for safety and efficacy.

08:03 EST VF Corp. CEO Steve Rendle retires, Benno Dorer named as interim CEO - VF Corp. announced that Benno Dorer, lead independent director of the VF board of directors, has been named interim president and CEO, effective immediately. Richard Carucci, a director on the board since 2009, will serve as interim chairman of the board. Dorer's appointment follows Steve Rendle's decision to retire from his position as chairman, president and CEO. The company has commenced a search for a permanent CEO and has retained an executive search firm to support its evaluation of internal and external candidates.

08:02 EST China Pharma acquires Dry Eye Disease Therapeutic Device Project - China Pharma Holdings announced the Acquisition of Dry Eye Disease Therapeutic Device Project. Li Zhilin, CEO of China Pharma said: "Due to the increasingly developed technology, the time and frequency of using the electronic products have significantly increased in recent years. In addition, with the aging of the population, DED has become the largest ophthalmic disease in China, and the diagnosis and treatment rate is expected to maintain an upward trend for a long time. What we acquired is an ophthalmic oxygen enriched atomization therapeutic device with a patent technology. This device is to fill in the vacuum of the current market demand in devices to treat DED, visual fatigue and other problems, as well as recovery after eye surgery. We plan to launch it to the market next year. We are confident that the launch of this product will bring excellent treatment experience to every DED patient, which will also boost the Company's sales. "

07:57 EST Advisory firms say Argo Group holders should vote for all director nominees - Argo Group International Holdings announced that leading independent proxy advisory firms, Institutional Shareholder Services and Glass Lewis & Co, have recommended that shareholders vote "FOR" all seven of Argo's highly qualified director nominees at the Company's upcoming Annual Meeting of Shareholders to be held on December 15. In addition, Voce Capital Management the owner of approximately 9.5% of the Company's common shares, has informed the Company that it has voted all of its shares on the BLUE proxy card in support of the seven Argo nominees at the Company's upcoming 2022 annual meeting. In making its recommendations, ISS stated in its December 2, 2022 report : "The dissident has not made a compelling case for change. The highest priority for ARGO is the ongoing strategic review. There is no reason to believe that the process is not being conducted to advance the best interests of shareholders, and there is no indication that a key competency or perspective is absent from the strategic review committee." "The addition of Dan Plants in early August only bolstered the board's credibility, particularly because he was appointed to chair the strategic review committee."

07:43 EST DMG Blockchain Solutions mines 88 bitcoin in November - DMG Blockchain Solutions announces November preliminary mining results. In November 2022, DMG mined 88 bitcoin with 0.83 EH/s realized hashrate. DMG's bitcoin balance as of November 30, 2022 was 389 bitcoin. Depending on the timing to receive shipments of ordered miners, DMG expects to grow its hashrate to 1 EH/s by the end of this calendar year or early 2023; this is subject to the receipt, installation and operation of the additional miners.

07:42 EST Adaptive Biotechnologies to present more than 30 abstracts at ASH meeting - Adaptive Biotechnologies will present data from more than 30 abstracts showcasing the benefit of Adaptive's next-generation sequencing, NGS,-based clonoSEQ Assay in measuring minimal residual disease, MRD, in blood cancer patients at the 64th Annual Meeting of the American Society of Hematology, ASH, taking place December 10-13, 2022. "The data presented at ASH continues to reinforce the value of serial MRD testing with clonoSEQ as a sensitive prognostic tool in real-world settings and in clinical trials," said Nitin Sood, chief commercial officer, MRD, Adaptive Biotechnologies. "Data continues to demonstrate that testing MRD at multiple timepoints throughout a patient's cancer journey is part of the new standard of care for most lymphoid malignancies and is critical to a physician's ability to assess prognosis, determine response to treatment, detect relapse, and ultimately optimize care." Data generated using clonoSEQ across various blood cancers will be featured in the selected 12 oral presentations and 21 posters listed below at ASH. Five of the presentations are studies using real-world evidence to demonstrate how serial clonoSEQ testing is being utilized in the clinic to inform physician decisions across indications and therapeutic regimens to guide personalized treatment plans, including discontinuation of therapy.

07:41 EST iSpecimen appoints Basile to board of directors - iSpecimen announced that the Company has appointed Joseph Basile to iSpecimen's Board of Directors, as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Basile is replacing Margaret Lawrence as an independent director. Basile has advised global Fortune 500 companies, mid-market public companies, private equity and venture capital backed companies, and family-owned companies. His experience includes work in the technology, life sciences, professional services, and education sectors. He is the founder and managing director of Pari Passu M&A Mediation.

07:39 EST Solid Biosciences closes acquisition of AavantiBio, $75M private placement - Solid Biosciences announced the closing of its acquisition of AavantiBio, a privately held gene therapy company focused on transforming the lives of patients with Friedreich's ataxia and rare cardiomyopathies, including its pipeline assets and net cash. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich's ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Bo Cumbo, the Chief Executive Officer of AavantiBio, will assume the role of President and CEO of Solid Biosciences. Concurrent with the closing of the merger, Solid closed the previously announced $75 million private placement with a select group of institutional investors and accredited investors. The private placement was led by existing investors Perceptive Advisors, LLC, RA Capital Management and Bain Capital Life Sciences, and other new and existing investors participating in the private placement include CaaS Capital Management, Invus, Laurion Capital Management and Pura Vida Investments. Solid's stockholders approved the issuance of shares of Solid common stock in the transactions on December 1, 2022, along with the other proposals presented at the meeting. Following the closing of the merger and private placement, Solid has total cash and investments of approximately $215 million. Solid expects this will be sufficient to fund the company's planned operating expenses and capital expenditure requirements into 2025 and enable the potential attainment of key milestones for the combined company's lead programs.

07:36 EST Athira Pharma presents preclinical data on ATH-1105 in ALS - Athira Pharma presented data highlighting the potential therapeutic benefits of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in a preclinical mouse model of amyotrophic lateral sclerosis. Data presented highlight the neuroprotective effects of daily ATH-1105 treatment in the TDP-43 mouse model of ALS. The study results show that compared to untreated TDP-43 controls: ATH-1105-treated mice were protected against loss of body weight and had significant improvement in motor function and coordination; ATH-1105-treated mice had significant improvements in nerve function; Biomarker assessments of ATH-1105-treated mice had significantly reduced plasma levels of inflammatory cytokines and neurofilament light, suggesting a reduction in systemic inflammation and neurodegeneration, respectively; Assessment of sciatic nerve histology showed that ATH-1105-treated mice had a significant increase in the number of axons, larger axonal diameters, and normal myelin thickness levels, suggestive of neuroprotection. "Importantly, these positive findings in this ALS model are consistent with data we have reported in preclinical models of other neurodegenerative diseases, which also showed that enhancing the HGF/MET neurotrophic system has a positive impact on neurodegeneration and neuroinflammation, and could be disease modifying," said Mark Litton, Ph.D., President and Chief Executive Officer of Athira Pharma. "We look forward to advancing ATH-1105 as a potential new therapy for debilitating neurodegenerative disorders such as ALS."

07:34 EST Nasdaq grants Windtree Therapeutics 180-day extendion to regain compliance - Windtree Therapeutics announced that the NASDAQ Stock Market has granted Windtree an additional 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2), following the expiration of the initial 180 days period to regain compliance on November 30, 2022. As a result of the extension, the Company now has until May 29, 2023 to regain compliance with the $1.00 minimum bid price rule requirement. If at any time before May 29, 2023, the bid price of the Company's common shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has achieved compliance with the bid price requirement. If the Company chooses to implement a reverse stock split to regain compliance, it must complete the reverse split no later than 10 business days prior to the expiration of the additional 180 calendar day period in order to timely regain compliance. If the Company does not regain compliance with the bid price requirement by May 29, 2023, Nasdaq will provide written notification to the Company that its shares will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. There can be no assurance that, if the Company does appeal a subsequent delisting determination, such appeal would be successful. The Company would remain listed pending the Panel's decision. The current notification from Nasdaq has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol "WINT".

07:34 EST Tradeweb Markets announces $300M share repurchase agreement - Tradeweb Markets announced that its board of directors has approved a share repurchase program. The company is authorized to repurchase up to $300M in shares of its Class A common stock, either in the open market, through privately negotiated transactions, through accelerated share repurchases or through the use of trading plans, each in accordance with applicable securities laws and other restrictions. The manner, timing and amount of any purchase will be based on an evaluation of market conditions, stock price and other factors. The program has no termination date, may be suspended or discontinued at any time and does not obligate the company to acquire any amount of Class A common stock.

07:33 EST Eltek awarded $1.1M follow-up order from defense customer - Eltek announced the company has received a follow-up purchase order in the amount of $1.1M from an existing customer in the defense sector. The original purchase order in the amount of $1.4M was received during the first quarter of 2022. The order will be supplied by Eltek over a period of four months commencing in March 2023.

07:32 EST Universal Display signs OLED supply, license agreements with Samsung Display - Universal Display announced the signing of long-term OLED material supply and license agreements with Samsung Display, or SDC, a global display manufacturing leader. These agreements affirm that Universal Display Corporation will continue to supply its proprietary UniversalPHOLED phosphorescent OLED materials and technology to Samsung Display for use in its OLED displays. The agreements are scheduled to run through December 31, 2027, and may be extended for an additional two-year period. Financial terms of the agreements have not been disclosed.

07:29 EST EHang appoints Nick Ning Yang to board of directors - EHang Holdings announced that Nick Ning Yang has been appointed as a new director to the Company's Board of Directors, effective December 5, 2022. The Board has reviewed and determined that Mr. Yang meets all the "independence" requirements under Rule 10A-3 of the United States Exchange Act of 1934 and Rule 5605 of the Nasdaq Stock Market Rules. Yang is a founding Partner of LeBox Capital, a venture investment fund established in 2011 that focuses on early-stage high growth TMT companies in China.

07:21 EST Century Casinos provides update on projects in Caruthersville, Missouri - Century Casinos (CNTY) broke ground on the new land-based casino and hotel development at Century Casino Caruthersville on Friday, December 2. The casino at Century Casino Caruthersville will offer 650 slot machines (with the possibility of an expansion of up to 140 additional slot machines), table games, a deli, and a bar. The 38-room hotel, which will be located in a hotel tower between the existing pavilion and the new casino, will provide scenic views of the Mississippi River and city of Caruthersville. The new casino and hotel are expected to open in late 2024, subject to final regulatory approval from the Missouri Gaming Commission as well as other state and local approvals. The Caruthersville Project is expected to cost approximately $51.9M. To finance the Caruthersville Project, the Company entered into an amendment to its Master Lease with VICI Properties Inc. (VICI). Following completion, VICI will own the real estate improvements associated with the Caruthersville Project. Annual rent under the Master Lease will increase by approximately $4.2M after completion of the Caruthersville Project. Following the groundbreaking ceremony, the company hosted a grand opening of the Farmstead, a 36-room hotel located near the existing pavilion and the new land-based casino and hotel development in Caruthersville. The Company bought the Farmstead land and building in July 2021 and completely renovated the hotel building into a contemporary Missouri farmhouse style hotel at a cost of approximately $3.7 million. The Farmstead will be the only hotel in Caruthersville until the new hotel at the land-based Century Casino Caruthersville is completed. Currently, the Company continues its work on the relocation of the casino floor of Century Casino Caruthersville from the riverboat and barge on the Mississippi river to a temporary location in the pavilion. The Company's goal is to have that relocation completed before the end of 2022. The record low water levels of the Mississippi River in October 2022 made the relocation to a temporary land-based facility necessary because the riverboat, which operated since 1994, was no longer accessible from the barge. The Missouri Gaming Commission approved the relocation to the temporary facility in October 2022. The casino will remain in the temporary facility until the time the new permanent land-based casino is completed. The pavilion, the Farmstead, parking, and the new land-based Caruthersville Project are all protected by a flood wall. As a result, the Company expects that casino operations in Caruthersville will no longer be affected by water levels in the Mississippi River.

07:18 EST Else Nutrition adds 150 retailers in 2H22 - ELSE NUTRITION HOLDINGS announces the addition of 150 retailers, more than doubling the number of retail stores selling Else Nutrition products in Southern California in the second half of 2022. The increase comes with the addition of regional retail partners such as Gelson's and additional stores from CVS Pharmacy and Walmart.

07:17 EST Brunswick Exploration expands option agreement with Osisko Development - Brunswick Exploration expanded its recently signed option agreement with Osisko Development to also acquire a 90% interest in the PLEX Project, which is located along the same fault structure that hosts Patriot Battery Metals' Corvette lithium project. The PLEX Project package contains a total of 375 claims, representing 19,175 hectares. The property is accessible year-round and located near the Trans-Taiga highway, providing access to the La Grande-4 hydroelectric complex. The Project is situated approximately 75 km west of Patriot Battery Metals' Project, along the La Grande shear zone which is host to the entire Corvette lithium trend. Compilation work by BRW has identified over 100 individual pegmatite outcrops and numerous pegmatite dykes on the Project of varying length, including one pegmatite dyke measuring 1.7 kilometres strike length. The latter was intersected in multiple drill holes by previous gold explorers between 2007 and 2014 but was only superficially described in drill logs and not assayed for Lithium-Cesium-Tantalum mineralization; the longest drill intersection of pegmatite measured 103 meters in length. The Project has historically never been explored for lithium mineralization. BRW intends to launch a regional prospecting campaign in late Q2 2023 to explore both the PLEX and Mythril Projects and multiple other smaller BRW claim packages located in the northern half of the James Bay-Eeyou Istchee region. The campaign will include sampling and analysis of pegmatite from recovered drill core on the PLEX Project and will likely lead to more follow-up trenching and/or drilling beyond BRW's current exploration program for 2023. The expanded Option allows BRW to acquire a 90% interest in the Project for a total consideration of 8,000,000 shares over a two-year period, upon closing of the option agreement under the following terms: An initial payment of 1,000,000 shares, within five business days of the Effective Date of the Agreement; A payment of 3,000,000 shares, on or before the 1st year anniversary of the Effective Date of the Agreement; A payment of 4,000,000 shares, on or before the 2nd year anniversary of the Effective Date of the Agreement. In order to exercise the Option; Brunswick Exploration shall fund an aggregate amount of $6,000,000 in Work Expenditures in accordance with the following schedule: An aggregate of $1,000,000 before the 1st year anniversary of the Effective Date; An aggregate of $2,000,000 before the 2nd year anniversary of the Effective Date; An aggregate of $4,000,000 before the 3rd year anniversary of the Effective Date; An aggregate of $6,000,000 before the 4th year anniversary of the Effective Date. Upon execution of the Option, BRW will retain a right of first refusal on ODEV's 10% ownership. Furthermore, ODEV will not be expected to fund its pro-rata share of the exploration budget following the exercise of the Option until the construction of a mine.

07:16 EST Syndax: FDA grants Breakthrough Therapy Designation for revumenib - Syndax Pharmaceuticals announced that the U.S. FDA has granted Breakthrough Therapy Designation for revumenib for the treatment of adult and pediatric patients with relapsed or refractory acute leukemia harboring a KMT2A rearrangement. Revumenib is the company's highly selective, oral menin inhibitor. The company remains on track to submit an NDA for revumenib by the end of 2023 with the potential for an expedited approval with a broad indication.

07:15 EST VICI Properties provides capital for Century Casinos' expansion - VICI Properties (VICI) announced that it will utilize its Partner Property Growth Fund to provide capital for an exciting expansion project for Century Casinos (CNTY). The project consists of a new land-based casino with an adjacent 38-room hotel tower at Century Casino Caruthersville, located in Caruthersville, Missouri. Pursuant to an amendment to the existing master lease between the parties, VICI will own the real estate improvements associated with these projects, which are expected to cost approximately $51.9M, and annual rent under the master lease with Century will increase by approximately $4.2M following completion of the projects. John Payne, President and Chief Operating Officer of VICI Properties, said, "We are very excited to continue to grow our partnership with Century by funding this expansion project through our Partner Property Growth Fund. Since we jointly acquired three regional assets in 2019, the Century team has significantly enhanced performance at the properties by fine-tuning operations and focusing intently on customer satisfaction. Our team, led by Danny Valoy and Elena Keil, has collaborated with Century to structure a transaction that greatly enhances the long-term value of the property in Caruthersville, provides Century with balance sheet flexibility and allows VICI to invest free cash flow, growing our AFFO without the need for external funding."

07:12 EST Verizon announces CEO of Verizon Consumer Group has stepped down - Verizon Communications announced that Manon Brouillette, CEO of Verizon Consumer Group, has stepped down from the role she has held since January 2022. Verizon Chairman and CEO Hans Vestberg has assumed responsibility for leading the Consumer Group in addition to his day-to-day responsibilities.

07:12 EST Lantheus announces proposed offering of $500M convertible senior notes - Lantheus Holdings announced that it intends to offer, subject to market conditions and other factors, $500 million in aggregate principal amount of the Company's convertible senior notes due 2027. The Notes are to be offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also expects to grant the initial purchasers of the Notes an option to purchase, within the 13-day period beginning on, and including, the initial closing date of the offering, up to an additional $75 million in aggregate principal amount of Notes. The Notes will be senior unsecured obligations of the Company. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Lantheus Medical Imaging, Inc., a direct wholly owned subsidiary of the Company. The Notes will mature on December 15, 2027, unless earlier redeemed, repurchased or converted. The Notes are expected to pay interest semi-annually in arrears. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company's common stock, or a combination of cash and shares of the Company's common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company's common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, the initial conversion rate and the other terms of the Notes will be determined upon pricing of the offering by negotiations between the Company and the initial purchasers of the Notes. The Company's board of directors has authorized the repurchase of up to $150 million in aggregate amount of its common stock under certain circumstances. The Company expects to use up to $75 million of the net proceeds from the offering of the Notes to repurchase shares of its common stock from purchasers of Notes in this offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. These repurchases could increase, or prevent a decrease in, the market price of the Company's common stock or the Notes concurrently with the pricing of the Notes, and could result in a higher effective conversion price for the Notes. The Company intends to use the remainder of the net proceeds from the offering of the Notes for general corporate purposes, including other repurchases of its common stock from time to time in an amount up to $75 million, working capital, capital expenditures, refinancing or repaying debt, payments related to the previously announced license and collaboration agreements with POINT Biopharma Global Inc. and with an affiliate thereof if the transactions contemplated by such agreements are consummated, potential acquisitions and strategic transactions.

07:11 EST Denali Therapeutics announces DNL343 interim Phase 1b data in ALS - Denali Therapeutics announced interim results from a Phase 1b study of its eIF2B agonist, DNL343, in participants with amyotrophic lateral sclerosis. Once-daily oral dosing with DNL343 for 28 days was generally well tolerated and demonstrated extensive BBB penetration as well as robust inhibition of biomarkers associated with the integrated stress response in blood samples from study participants. By inhibiting the ISR pathway, DNL343 is intended to prevent or slow disease progression associated with stress granule formation and TDP-43 aggregation, a hallmark pathology present in nearly all individuals with ALS. Denali also announced initiation of the design phase of a Phase 2/3 study for entry into the HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with the Northeast ALS Consortium. "These initial Phase 1b results with DNL343 in ALS are consistent with our previously reported Phase 1 healthy volunteer data and are an important milestone for the program," said Carole Ho, M.D., Chief Medical Officer at Denali. "The data continue to support late-stage development plans for DNL343, and we are excited to be collaborating with the HEALEY ALS Platform Trial team in our unified effort to advance potential treatment options for people living with ALS."

07:10 EST Marimaca Copper reports results from northern MOD infill drilling - Marimaca Copper announces further results from the 2022 infill drilling campaign. The results further improve confidence in the newly identified higher-grade centres located in the northern Marimaca Oxide Deposit, MOD, which were intersected in previously reported drill holes from the 2022 campaign. Sergio Rivera, VP Exploration of Marimaca Copper, commented: "The infill drilling results from Marimaca continue to provide positive surprises and we are very pleased with the current results... The current results provide additional support to the exceptional results released on 21 November 2022, and have further improved our interpretation of the geology and confidence in continuity of the copper mineralization. Most importantly, both sets of results demonstrate upside to the previously interpolated grades from our 2022 MRE for the northern MOD as we prepare for our final updated resource in early 2023..."

07:08 EST RedHill Biopharma's Aemcolo granted FDA QIDP 5-year exclusivity extension - RedHill Biopharma announced that the U.S. FDA's Exclusivity Board has granted Aemcolo five years' exclusivity under the Generating Antibiotic Incentives Now Act Qualified Infectious Disease Product designation, in addition to the five years' data exclusivity granted as a new chemical entity for the treatment of travelers' diarrhea caused by non-invasive strains of Escherichia coli in adults.

07:08 EST Old Dominion reports November revenue per day up 7.3% - Old Dominion reported certain less-than-truckload, or LTL, operating metrics for November. Revenue per day increased 7.3% as compared to November 2021 due to an increase in LTL revenue per hundredweight that was slightly offset by an 8.6% decrease in LTL tons per day. The change in LTL tons per day was attributable to a 7.3% decrease in LTL shipments per day and a 1.4% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 17.3% and 8.6%, respectively, as compared to the same period last year.

07:06 EST Canadian Solar signs 256 MW solar module contract with SOLA Group - Canadian Solar announced that its majority-owned subsidiary, CSI Solar Co., Ltd., signed a 256 MW solar module contract with SOLA Group, a Cape Town-based independent power producer. The 256 MWs will supply the first two largest utility-scale solar power projects in South Africa, which are based on private power purchase agreements. The two solar projects are 126 MWp and 130 MWp each in size, located in South Africa's North West Province. Both projects are developed and will be operated by SOLA Group and its partners. Construction started in October 2022, and commercial operation is planned for the first quarter of 2024. These two solar power projects cover an area of approximately 430ha. Once in operation, they are estimated to generate approximately 580 GWh of clean, renewable electricity every year, equivalent to powering 40,000 households and reducing 595 tons CO2 emissions each year.

07:05 EST Tonix announces collaboration with Boston Children's Hospital for TNX-15001 - Tonix Pharmaceuticals announced that it has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-15001 for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in animals. The primary objective of the preclinical research study is to study the activity of TNX-1500 administered prophylactically to modify GvHD progression in animals after HCT to support an Investigational New Drug application for human studies. A Phase 1 study of TNX-1500 to assess pharmacokinetics and tolerability is expected to start in the first half of 2023. Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals said, "Stem cell transplantation is an essential component of the treatment of several blood cell or hematologic cancers, but GvHD remains the most deadly complication, and limits the success of this otherwise life-saving treatment. To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejection or GvHD with acceptable levels of tolerability. TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to decrease FcgammaRII binding and to reduce the potential for thrombosis. We are excited to sponsor this study of testing anti-CD40L in HCT to potentially replace cyclophosphamide in the post-transplant setting. A positive result would potentially support an IND and human studies."

07:04 EST Amryt Pharma announces EC approves Mycapssa for treatment of acromegaly - Amryt announces the European Commission, EC, approval of Mycapssa in the European Union, EU, for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. The centralized marketing authorisation will be valid in all EU Member States as well as in Iceland, Liechtenstein, and Norway. The EC approval of Mycapssa is supported by efficacy and safety data from three Phase 3 studies in acromegaly patients including the pivotal MPOWERED Phase 3 trial. Dr Joe Wiley, CEO of Amryt Pharma, commented: "The EC approval of Mycapssa(R) is a significant development for acromegaly sufferers in Europe and Mycapssa will be the first and only oral somatostatin analog approved in the EU."

07:03 EST BioRestorative enters agreement with Regenexx, granted exclusive license rights - BioRestorative Therapies announced an agreement with Regenexx pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive. The intellectual property now exclusively licensed to the Company represents important technological framework for BRTX's disc/spine technology related to the Company's BRTX-100 lead clinical program, currently in a Phase 2 trial with approximately 15 sites selected across the United States. "This is an important event for BioRestorative. We are thrilled to now have through this agreement an exclusive license with regard to Regenexx's technology," said Lance Alstodt, Chief Executive Officer at BioRestorative. "With this agreement, coupled with our unique in-house research and manufacturing capabilities, we aim to create a new generation of cell-based products to induce long-term and sustained pain relief for patients suffering from musculoskeletal indications. Approximately $40 billion is spent annually on invasive surgical procedures. With BRTX-100, the Company is seeking to provide a paradigm shifting, non-invasive solution to millions of patients worldwide."

07:01 EST Webster Financial to acquire interLINK, terms not disclosed - Webster Financial announced that its principal bank subsidiary, Webster Bank, N.A., has signed a definitive agreement to acquire StoneCastle Insured Sweep, LLC (d/b/a interLINK), a subsidiary of StoneCastle Partners. interLINK is a technology-enabled deposit management platform administering over $9B of deposits from FDIC-insured cash sweep programs between banks and broker/dealers and clearing firms. interLINK leverages highly scalable technology, generating significant liquidity at minimal operating cost. Under the agreement, interLINK will continue to operate and serve its broker/dealer and clearing firm clients as it does today. Financial terms of the transaction were not disclosed. The transaction is expected to close in the first quarter of 2023.

06:48 EST Foxconn 'gradually moving' toward restoring normal production capacity - The company said, "Since the outbreak of the epidemic in October, we have been in close contact and cooperation with the local government and customer. In compliance with the official epidemic prevention policy, safeguarding employees' health and ensuring safe production has always been the primary operating principle that the company adheres to. We are making every effort to protect the rights and interests of employees, so that current employees and new hires receive the best care to get through this epidemic together. At present, the overall epidemic situation has been brought under control with November being the most affected period by the epidemic. In addition to re-allocating production capacity of different factories,we have also started to recruit new employees, and are gradually moving toward the direction of restoring production capacity to normal. The outlook for the fourth quarter is expected to be roughly in line with the market consensus." The company also reported November revenue down 11.4% year-over-year. Reference Link

06:46 EST Broadridge appoints Martin Koopman as chief product officer - Broadridge announced the appointment of Martin Koopman as chief product officer, effective January 1, 2023. In this role, Martin will lead the product management team working across all business units to collectively drive Broadridge's delivery of SaaS and other service offerings to leading financial services clients. He will be responsible for Broadridge's enterprise product vision and strategy, building enterprise-wide platforms to benefit Broadridge clients, empowering product management teams, and accelerating innovation in partnership with our technology teams.

06:42 EST Diffusion Pharmaceuticals urges shareholders to vote for six board nominees - Diffusion Pharmaceuticals sent a letter to its stockholders. The letter highlights the strength, experience and quality of the company's board of directors as it continues to take steps to unlock stockholder value through a strategic review process. The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space, and LifeSci-affiliated funds' recent nomination of an unqualified dissident slate of nominees for election as directors at the company's 2022 Annual Meeting of Stockholders. "Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process. Diffusion received bids from more than 15 companies participating in review process. LifeSci invited to participate in review process on same terms as all other bidders following submission of client's unsolicited offer, but LifeSci instead chose to launch a proxy contest against our highly qualified board. LifeSci's track record demonstrates a highly troubling pattern of self-dealing and stockholder value destruction, including more than $1.3 billion of stockholder losses in recent SPAC transactions. Diffusion's board and management are fully committed to maximizing value for all stockholders through the completion of the strategic review process, notwithstanding LifeSci's self-serving attempts to disrupt the process Diffusion urges stockholders to vote 'FOR' each of the Board's six nominees for director on your WHITE proxy card."

06:37 EST HilleVax reports results from ongoing Phase 2b trial of HIL-214 - HilleVax reported results from a prespecified immunogenicity analysis of the 203 subjects enrolled in the run-in cohort of NEST-IN1, the company's ongoing Phase 2b trial for HIL-214, its investigational virus-like particle based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis in infants. These results follow the previously announced positive recommendation from an independent safety data monitoring committee based on this same cohort. Immunogenicity Results: Geometric Mean Titers of pan-IG antibodies 28 days following the second dose were 11,102.0 IU/mL and 2,185.5 IU/mL for GI.1 and GII.4, respectively, for HIL-214 compared to 59.6 IU/mL and 73.5 IU/mL for GI.1 and GII.4, respectively, for placebo. These titers corresponded to a Geometric Mean Fold Rise versus baseline of more than 18-fold for HIL-214. Seroresponse rates for HIL-214, defined in NOR-212 as the percentage of subjects with at least a 4-fold increase in pan-Ig antibody titers 28 days following the second dose compared to pre-vaccination baseline, were 99.0% for GI.1 and 86.9% for GII.4. SRRs for placebo were 4.1% and 3.1% for GI.1 and GII.4, respectively. "We are very pleased with the immunogenicity results from the NEST-IN1 run-in cohort which were consistent with our expectations based on previous studies of HIL-214 given to infants," said Rob Hershberg, MD, PhD, Chairman and CEO of HilleVax. "We now look forward to the full NEST-IN1 topline safety and efficacy data which remain on-track for the second half of 2023."

06:35 EST TFF Pharmaceuticals announces CEO Glenn Mattes to step down - TFF Pharmaceuticals announced that Glenn Mattes will step down as CEO and Member of the Board of Directors. Dr. Harlan Weisman, Vice Chairman of the Board, has been appointed Interim CEO, effective December 5. Harlan F. Weisman, M.D. has more than 30 years of experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services.

06:32 EST Wireless Telecom sells CommAgility LTD to E-Space for $14.5M - Wireless Telecom Group announced it entered into a definitive agreement to sell its radio, baseband and software segment, CommAgility LTD., to global space company, E-Space. The purchase price is $14.5M, inclusive of $13.75M in cash consideration and a $750,000 note payable, subject to agreed-upon reductions. The transaction was the result of the company's previously disclosed process for evaluating strategic alternatives. The Purchase Agreement includes customary terms and conditions, including certain adjustments to the purchase price based on transaction costs, net working capital and indebtedness. The transaction, which was unanimously approved by the Board of Directors of both companies, is subject to various terms and conditions, including customary closing conditions. The transaction, which is expected to be completed no later than January 31, 2023, is subject to customary closing conditions, including regulatory approvals. As a result of this transaction, Wireless Telecom Group is now comprised solely of Test & Measurement brands including Boonton, Holzworth and Noisecom. Wireless Telecom Group continues to explore strategic alternatives for the company to enhance value for shareholders. No timetable has been set for the Company's process. Wireless Telecom Group does not expect to comment further or update the market with any additional information on the process unless and until its Board of Directors has approved a specific transaction or otherwise deems disclosure appropriate or necessary. There is no assurance that continuing to pursue strategic alternatives will result in Wireless Telecom Group further changing its current business plan, pursuing a particular transaction or completing any such transaction.

06:08 EST FP Credit Partners II offers to buy 7.5M Class A Ordinary shares of Pathfinder - FP Credit Partners II, L.P. and FP Credit Partners Phoenix II, L.P. have commenced a cash tender offer to purchase up to an aggregate of 7.5M Class A Ordinary shares, $0.0001 par value per share, of Pathfinder Acquisition Corporation, a Cayman Islands Exempted company incorporated with limited liability, at a price of $10.00 in cash per Class A Share, without interest on the purchase price and less any applicable withholding taxes. Each of the Class A Shares was sold, together with one-fifth of one redeemable warrant exercisable for one Class A Share, as part of the units issued in the company's initial public offering pursuant to a prospectus dated February 16, 2021. Beginning on April 9, 2021, holders of the units sold in the Company's initial public offering were able to elect to separate the units into their component parts and begin trading the Class A Shares and warrants separately.

06:06 EST China Yuchai announces end-use check conducted on GYMCL - China Yuchai announced an end-use check has been conducted on its subsidiary, Guangxi Yuchai Machinery, or GYMCL, by the U.S. Department of Commerce. As at the date of this announcement, GYMCL's business continues to operate normally with no major supply chain impact. The company will make further announcements as and when appropriate in the event of any further material development on the matter.

06:04 EST Ideaya Biosciences granted fast track designation for darovasertib - Ideaya Biosciences announced that the FDA has granted fast track designation to Ideaya's development program investigating darovasertib, a potential first-in-class protein kinase C, or PKC, inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.

06:02 EST KBR awarded contract to design offshore energy storage for CrossWind - KBR (KBR) announced it has been awarded a contract to provide engineering services for an offshore energy storage project for CrossWind, a joint venture, or JV, between Shell (SHEL) and Dutch utility company, Eneco. KBR will perform a front-end engineering design of the baseload power hub, or BLPH, for the Hollandse Kust wind farm located offshore Netherlands. KBR and Shell will design and develop facilities that integrate lithium-ion battery storage and green hydrogen electrolysis production at megawatt scale. The design will enable hydrogen production and electricity storage in periods of high-power production and will convert hydrogen to electricity, via a fuel cell, during periods of lower power production.

05:20 EST MaxCyte, Curamys announce SPL for cell and gene therapies - MaxCyte and Curamys announced the signing of a strategic platform license, or SPL. Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue. Curamys is focused on developing treatments for genetic and degenerative diseases through its specialized cell fusion technology, based on the concept that apoptotic or dying cells can be regenerated by fusing them with healthy normal cells. Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of a treatments for genetic and rare intractable diseases at the cellular level.

05:08 EST Fortuna Silver Mines provides update on Seguela gold Project - Fortuna Silver Mines provided an update on its exploration program at the Seguela gold Project located in Cote d'Ivoire. Sunbird's new resource estimation is in addition to Seguela's current Mineral Reserves of 12.1 Mt averaging 2.80 g/t Au containing 1.09 Moz. Exploration drilling at Sunbird since the release of the maiden Inferred Mineral Resource has resulted in an upgraded estimate, including a maiden Indicated Mineral Resource of 3.2 million tons at an average grade of 2.74 g/t gold containing 279,000 ounces and an Inferred Mineral Resource of 4.2 million tons at an average grade of 3.74 g/t gold containing 506,000 ounces.